BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

Q4 2021 BioXcel Therapeutics Inc Earnings Call Transcript

Mar 10, 2022 / 01:30PM GMT
Release Date Price: €16.71 (+3.21%)
Operator

Good morning, and welcome to BioXcel Therapeutics' Fourth Quarter and Full Year 2022 Financial Results Conference Call. (Operator Instructions)

Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.

Risk factors that may affect results are detailed in the company's most recent public filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarterly period ended September 30, 2021, as will be updated by its annual report on Form 10-K for the year ended December 31, 2021, which can be found at bioxceltherapeutics.com or on sec.gov.

As a reminder, today's conference is being recorded. Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Dr. Vince O

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot